Asia-Pacific In-Vitro Diagnostic (IVD) Market Analysis

26 Oct 2010 • by Natalie Aster

LONDON – “Asia can be regarded as one of the most potential healthcare markets in the world. Rapid growth in population, expanding network of healthcare services and rising prevalence of chronic and infectious diseases has significantly driven the growth in demand for healthcare and diagnostic services in the region.”

MarketPublishers Ltd. announces that new report Asia-Pacific In-Vitro Diagnostic (IVD) Market Analysis elaborated by Religare Info Services is available in its catalogue. The present report gives an insight into the various developments that are currently taking place in the Kingdom’s higher education sector and substantiates key findings with necessary statistics.

Report Details

Asia-Pacific In-Vitro Diagnostic (IVD) Market Analysis

Published: September 2010
Pages: 40
Price: US$ 1,100.00

Report Sample Abstract:

With the increasing concern about healthcare among population, the demand for diagnostic services in the country has been continuously surging. This in turn has resulted into the emergence of new market opportunity for the diagnostic service providers in the region. Among some most emerging segments in the industry. Point of Care tests and SMBG are anticipated to experience most significant growth in demand due to increasing prevalence of diabetes and obesity in the Asian countries. Besides, the innovation in Molecular diagnostic segments is also likely to register a robust growth in the markets. Backed by the demand, the market for In Vitro Diagnostic in Asia Pacific is expected to post revenues worth USD 7.6 billion by this year end.

It is seen that the concept of healthcare services has been transitioned to “Wellness” from the traditional ‘Sickcare’ approach, a shift in focus from treatment to prevention. This has led to the increased focus on diagnostic segment like Point of Tests and SMBG. Resultantly, these tests have posted a high growth over the last few years and having large share in the market. In 2010, the SMBG tests segments are anticipated to dominate the market with more than 25 per cent share. This will be followed by Immunochemistry and clinical chemistry test. However, the share of these traditional tests (Immunochemistry and clinical chemistry) is likely to reduce in future.

Asia Pacific – IVD Market by Segments (%) 2010

On geographic level, Japan is largest market followed by China and Australia. However, in terms of the growth rate China and India are anticipated to be on top in future. Besides, the South East Asian markets like Malaysia and Singapore are also expected to post strong growth on the back of increasing healthcare facilities development.


To order the report or ask for free sample pages contact


MarketPublishers, Ltd.

Mrs. Alla Martin

Tel: +44 208 123 2220

Fax: +44 207 900 3970